Welton Washington, MD
Psychiatry · Ypsilanti, MINPI 1841201290
Payments from drug & device makers
Across 1,979 payments — averaging $728.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377K
- Otsuka America Pharmaceutical, Inc.$236K
- Teva Pharmaceuticals USA, Inc.$178K
- Alkermes, Inc.$177K
- AbbVie$173K
- Vanda Pharmaceuticals Inc.$141K
- plus $160K from 12 others
What the payments were for
- Consulting fees$42,0183%
- Speaking & faculty fees$1,287,61389%
- Travel & lodging$65,9145%
- Food & beverage$45,6713%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 394 | $377,098 |
| Otsuka America Pharmaceutical, Inc. | 288 | $236,000 |
| Teva Pharmaceuticals USA, Inc. | 307 | $177,653 |
| Alkermes, Inc. | 244 | $176,702 |
| AbbVie(2 entities) | 231 | $173,418 |
| Vanda Pharmaceuticals Inc. | 208 | $140,984 |
| E.r. Squibb & Sons, L.L.C. | 170 | $138,788 |
| Sunovion Pharmaceuticals Inc. | 74 | $9,955 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $9,795 |
| Johnson & Johnson | 17 | $314 |
| Indivior Inc. | 14 | $281 |
| Neurocrine Biosciences, Inc. | 7 | $145 |
| Corium, LLC | 2 | $131 |
| Lundbeck LLC | 2 | $60 |
| Acadia Pharmaceuticals Inc | 1 | $53 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$524,215
- CAPLYTA$370,963
- REXULTI$175,804
- VRAYLAR$167,897
- ARISTADA$152,898
- Fanapt$138,576
- COBENFY$92,861
- AUSTEDO$77,396
- ABILIFY MAINTENA$59,853
- Austedo XR$51,785
- UZEDY$42,887
- ARISTADA INITIO$38,224
- ABILIFY ASIMTUFII$23,299
- TRINTELLIX$9,646
- LATUDA$8,920
- VIIBRYD$200
- NUEDEXTA$125
- INVEGA SUSTENNA$125
- ADLARITY$115
How this compares
$1,441,454 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 34 | $355,569 |
| Invega TrinzaPaliperidone Palmitate | 42 | $241,329 |
| CaplytaLumateperone Tosylate | 73 | $182,061 |
| Abilify MaintenaAripiprazole | 64 | $168,883 |
| Invega SustennaPaliperidone Palmitate | 72 | $131,649 |
| Abilify AsimtufiiAripiprazole | 22 | $127,397 |
| RexultiBrexpiprazole | 55 | $83,694 |
| VraylarCariprazine Hcl | 42 | $60,411 |
| TrintellixVortioxetine Hydrobromide | 89 | $50,697 |
| Lurasidone Hcl | 172 | $46,584 |
| VyvanseLisdexamfetamine Dimesylate | 85 | $32,847 |
| EmsamSelegiline | 14 | $32,590 |
| MounjaroTirzepatide | 20 | $21,598 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $21,292 |
| QuviviqDaridorexant Hcl | 39 | $18,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $314 | $388,014126 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $236,000 | $379,975141 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $177,653 | $355,56934 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $377,098 | $182,06173 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $9,795 | $83,544174 claims |
| AbbVieVraylar | $173,418 | $60,41142 claims |
| Alkermes, Inc.Lybalvi | $176,702 | $21,29214 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $32 | $18,04839 claims |
| Axsome Therapeutics, Inc.Auvelity | $33 | $17,67917 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $140,984 | $12,78711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Ypsilanti
- Andreas SidiropoulasDetroit$2.8M
- Joel YoungRochester Hills$1.9M
- Rajaprabhakaran RajarethinamAnn Arbor$1.2M
- Eric AchtyesGrand Rapids$705K
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Brian MickeyAnn Arbor$490K
- Sagar ParikhAnn Arbor$331K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.